Aerie Pharmaceuticals Inc (AERI) : Foresite Capital Management Ii scooped up 25,913 additional shares in Aerie Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 975,285 shares of Aerie Pharmaceuticals Inc which is valued at $17,974,503.Aerie Pharmaceuticals Inc makes up approximately 11.40% of Foresite Capital Management Ii’s portfolio.
Other Hedge Funds, Including , New York State Common Retirement Fund boosted its stake in AERI in the latest quarter, The investment management firm added 3,900 additional shares and now holds a total of 32,547 shares of Aerie Pharmaceuticals Inc which is valued at $599,841. Gsa Capital Partners Llp added AERI to its portfolio by purchasing 12,437 company shares during the most recent quarter which is valued at $230,085. Aerie Pharmaceuticals Inc makes up approx 0.01% of Gsa Capital Partners Llp’s portfolio.Swiss National Bank boosted its stake in AERI in the latest quarter, The investment management firm added 5,100 additional shares and now holds a total of 38,200 shares of Aerie Pharmaceuticals Inc which is valued at $688,746. Quantbot Technologies Lp sold out all of its stake in AERI during the most recent quarter. The investment firm sold 9,530 shares of AERI which is valued $171,826.
Aerie Pharmaceuticals Inc opened for trading at $18.81 and hit $19.03 on the upside on Monday, eventually ending the session at $18.99, with a gain of 1.17% or 0.22 points. The heightened volatility saw the trading volume jump to 2,29,985 shares. Company has a market cap of $530 M.
Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. Cantor Fitzgerald Resumed Aerie Pharmaceuticals Inc on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $44.
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.